RDS

Global $4.93 Bn Neonatal Intensive Care Market Trends, Competitive Analysis and Forecasts, 2018-2023 & 2024-2030 - ResearchAndMarkets.com

Retrieved on: 
Monday, April 29, 2024
Medical Devices, Health, Consumer, Hospitals, Baby, Maternity, General Health, Conditional sentence, Hypothermia, Mortality, NICU, Humidity, Infant, Risk, Hospital, Page, Death, Jaundice, SWOT analysis, Medicine, Research, Light, Growth, Heart rate, Observation, Application, Incidence, Patient, Developed country, European Journal, White lung, Pediatrics, Temperature, Government, RDS, Prevalence, Disease, Dietary supplement

North America dominated the global neonatal intensive care market in 2023, followed by Europe.

Key Points: 
  • North America dominated the global neonatal intensive care market in 2023, followed by Europe.
  • Neonatal monitoring devices such as cardiac monitors are used in neonatal intensive care units for continuous monitoring of neonates.
  • The neonatal & pediatric hospital facilities dominate the global neonatal intensive care market because of their specialized information, dedicated infrastructure, and comprehensive services.
  • The increasing number of maternity hospitals offering neonatal intensive care services worldwide increases the popularity of this segment.

WestPark Announces Closing of a $6,000,000 Initial Public Offering for CDT Environmental (NASDAQ: CDTG)

Retrieved on: 
Tuesday, April 23, 2024
Utilities, Construction & Property, Finance, Energy, Building Systems, Banking, Professional Services, Other Construction & Property, Sale, Prospectus, RDS, Suite, Software, Sewage, ATM, Form, IPO, CDT, Biotechnology, Health, Star, Security (finance)

WestPark Capital today announced the closing of a $6,000,000 IPO for CDT Environmental Technology Investment Holdings Limited (“CDT”).

Key Points: 
  • WestPark Capital today announced the closing of a $6,000,000 IPO for CDT Environmental Technology Investment Holdings Limited (“CDT”).
  • The IPO consisted of 1,500,000 ordinary shares at a public offering price of $4.00 per share resulting in gross proceeds of $6,000,000, before offering expenses.
  • WestPark Capital, Inc. (“WestPark Capital”) was the sole book-running manager for the offering.
  • WestPark Capital provides a comprehensive range of corporate finance services, including initial public offerings, follow-on offerings, private placements, CMPOs, RDs, ATM, SIPOs and corporate finance advisory services.

Chiesi Group's 2023 Revenue Surpasses €3 Billion Mark, Reflecting 10% Growth Year-on-Year (+12% @CER), Underlining Commitment to Innovative, Sustainable Practices

Retrieved on: 
Monday, April 22, 2024
Carbon, Science, Corporation, Enzyme replacement therapy, FDA, AIR, License, International, RARE, Investment, Climate, Fabry disease, Climate change, CER, B Corporation (certification), CDP, Partnership, Empowerment, Alpha-mannosidosis, Parent, CARE, Chronic obstructive pulmonary disease, Environment, Culture, Benefit corporation, Patient, Science Based Targets initiative, Bronchiectasis, Acquisition, Caregiver, Epidermolysis bullosa, GHG, Place of birth, Health, Neonatology, Ethics, Asthma, RDS, Infant respiratory distress syndrome, Growth, Carbon Disclosure Project, COPD, Pharmaceutical industry

PARMA, Italy, April 22, 2024 /PRNewswire/ -- In 2023, Chiesi, a research-oriented international biopharmaceutical group headquartered in Parma (Italy), with 31 affiliates worldwide, showcased the efficacy of its operating model centred around shared value, sustainability, and high ethical standards. Through this approach, Chiesi continues to deliver tangible benefits for patients, people, and the planet.

Key Points: 
  • Chiesi's fixed triple formulation for the treatment of asthma and COPD (Chronic Obstructive Pulmonary Disease) achieved a 27% @CER growth.
  • Also, in 2023 it was introduced in China, presenting a pivotal opportunity for growth and expanding access to treatment for more patients.
  • In March 2023, Chiesi enriched its AIR portfolio thanks to the partnership with Affibody AB to develop and commercialize innovative treatments for respiratory diseases.
  • In November 2023, Chiesi signed a License Agreement with Haisco Pharmaceutical to develop, manufacture, and commercialise a novel solution for bronchiectasis.

ND3 Inc. Awarded $34.4 Million Contract to Support the 81st Reserve Support Command

Retrieved on: 
Monday, April 15, 2024
ECS, RDS, Army Reserve, United States Army Reserve, Partnership, United States Army, MRSC, CONUS, Army Reserve Command, Contiguous United States, Veteran, HQ, ND3, USARC, Airline

COLUMBIA, S.C., April 15, 2024 /PRNewswire/ -- ND3 is proud to announce it has been awarded a non-personal services contract valued at $34.4 million for the U.S. Army Reserve Command's (USARC) 81st Readiness Divisions (RDs).

Key Points: 
  • COLUMBIA, S.C., April 15, 2024 /PRNewswire/ -- ND3 is proud to announce it has been awarded a non-personal services contract valued at $34.4 million for the U.S. Army Reserve Command's (USARC) 81st Readiness Divisions (RDs).
  • We are honored to be a part of helping the US Military by providing exceptional service and equipment.
  • We look forward to building a strong partnership with the 81st MRSC and contributing to their success."
  • This contract win marks a significant step forward for ND3 as it expands its capabilities to serve the U.S. Military in a new capacity.

Rapidus announces U.S. subsidiary and opens Silicon Valley office; names Henri Richard as GM and president of Rapidus Design Solutions

Retrieved on: 
Thursday, April 11, 2024
Cloud, AMD, Organization, AI, Quantum computing, City, Partnership, Rapidus, Research, Semiconductor, SanDisk, Retirement, Silicon, Sony, NetApp, Marketing, RDS, IIM, IBM

Richard—who effectively came out of retirement to work for Rapidus— brings decades of leadership experience in sales, marketing and customer support to his new role.

Key Points: 
  • Richard—who effectively came out of retirement to work for Rapidus— brings decades of leadership experience in sales, marketing and customer support to his new role.
  • He's held executive positions at a wide range of industry-leading companies including AMD, Freescale, IBM, NetApp and SanDisk, among others.
  • Richard has strong relationships in the industry and has already assembled the core leadership team for Rapidus Americas sales and marketing.
  • "Working together with Rapidus engineers at the Albany NanoTech Complex, we are making tremendous strides for our 2nm joint development project."

Super Hi-Fi introduces StreamPlayer 1, the set-and-forget transmitter-based playout device

Retrieved on: 
Thursday, April 11, 2024
HD Radio, Internet, Radio, AI, High fidelity, Partnership, HD, LOS, Atmosphere, RDS, Television

LOS ANGELES, April 11, 2024 /PRNewswire-PRWeb/ -- Super Hi-Fi, the leader in AI-powered radio services for broadcast and digital media companies, today announced StreamPlayer 1, a new cost-efficient transmitter-based cloud-playout device designed for FM, HD Radio, and DAB/DAB+ broadcasts. With its seamless integration with Super Hi-Fi's HLS+ streaming technology and robust features, StreamPlayer 1 ensures high quality uninterrupted broadcasting, even in the event of internet outages.

Key Points: 
  • With its seamless integration with Super Hi-Fi's HLS+ streaming technology and robust features, StreamPlayer 1 ensures high quality uninterrupted broadcasting, even in the event of internet outages.
  • Key Features of StreamPlayer 1 Include:
    Plug and Play Setup: Simply connect StreamPlayer 1 to power and internet, and watch as StreamPlayer 1 automatically configures itself for seamless playout.
  • High-Quality Hardware: Built in partnership with Barix, StreamPlayer 1 delivers consistent, excellent performance under any circumstance, ensuring the highest quality broadcasting experience.
  • StreamPlayer 1, coupled with Super Hi-Fi's Program Director, offers the simplest way to manage a high-quality broadcast operation from anywhere.

Orphan designation: 6'-(R)-methyl-5-O-(5-amino-5,6-dideoxy-α-L-talofuranosyl)-paromamine sulfate Treatment of mucopolysaccharidosis type I, 22/09/2016 Positive

Retrieved on: 
Thursday, April 18, 2024
Eurostat, Diagnosis, Civil service commission, Death, Glycosaminoglycan, B cell, Enzyme, Mutation, Medicine, Cell, Mental disability, Disease, Patient, Committee, Knowledge, Scheie syndrome, Regulation, EMA, IRIS, Periodic breathing, Mucopolysaccharidosis, European, COMP, Enzyme replacement therapy, European Commission, Safety, DSM-IV codes, IQVIA, Marketing, Haematopoiesis, Liver, RDS, FGK, Hurler syndrome, MPS, Pharmaceutical industry

Orphan designation: 6'-(R)-methyl-5-O-(5-amino-5,6-dideoxy-α-L-talofuranosyl)-paromamine sulfate Treatment of mucopolysaccharidosis type I, 22/09/2016 Positive

Key Points: 


Orphan designation: 6'-(R)-methyl-5-O-(5-amino-5,6-dideoxy-α-L-talofuranosyl)-paromamine sulfate Treatment of mucopolysaccharidosis type I, 22/09/2016 Positive

Radisson Announces Re-Appointment of Denis V Lachance as Interim President & Chief Executive

Retrieved on: 
Monday, April 1, 2024
Interim, OTCQB, Gold, RDS

ROUYN-NORANDA, Quebec, April 01, 2024 (GLOBE NEWSWIRE) -- Radisson Mining Resources Inc. (TSX-V: RDS, OTCQB: RMRDF) (“Radisson” or the “Company”) announces the re-appointment of Denis V Lachance as Interim President & Chief Executive Officer.

Key Points: 
  • ROUYN-NORANDA, Quebec, April 01, 2024 (GLOBE NEWSWIRE) -- Radisson Mining Resources Inc. (TSX-V: RDS, OTCQB: RMRDF) (“Radisson” or the “Company”) announces the re-appointment of Denis V Lachance as Interim President & Chief Executive Officer.
  • Following an initial agreement signed on February 16, 2024, to have Brett Richards join Radisson as President and CEO on April 1, 2024, the Company and Mr. Richards have mutually agreed to terminate the agreement.
  • Radisson is a gold exploration company focused on its 100% owned O’Brien project, located in the Bousquet-Cadillac mining camp along the world-renowned Larder-Lake-Cadillac Break in Abitibi, Québec.
  • The project hosts the former O’Brien Mine, considered to have been Québec’s highest-grade gold producer during its production.

Precisely Supports Amazon RDS for Db2 Service with Real-Time Data Integration Capabilities

Retrieved on: 
Wednesday, April 3, 2024
Software, Data Analytics, Internet, Data Management, Professional Services, Technology, Mobile, Wireless, Security, Organization, Amazon, Connect, IBM Z, News, Amazon Relational Database Service, IBM, AWS, AS/400, Amazon Web Services, Investment, IBM Db2, RDS, Online shopping

Precisely , a global leader in data integrity, today announced that its Precisely Connect data integration solution now supports Amazon Relational Database Service (Amazon RDS) for Db2, simplifying migration from customers’ Database 2 databases to Amazon Web Services (AWS) and helping organizations achieve greater scale and gain new insights from analytic workloads.

Key Points: 
  • Precisely , a global leader in data integrity, today announced that its Precisely Connect data integration solution now supports Amazon Relational Database Service (Amazon RDS) for Db2, simplifying migration from customers’ Database 2 databases to Amazon Web Services (AWS) and helping organizations achieve greater scale and gain new insights from analytic workloads.
  • It follows the news of Precisely Connect’s Amazon RDS Ready Partner designation and the recent expansion to the AWS Mainframe Modernization Data Replication with Precisely service.
  • AWS announced general availability of Amazon RDS for Db2 at the end of last year, a service which makes it easy to set up, operate, and scale Db2 databases in the cloud.
  • Today’s announcement highlights the value Precisely provides in supporting Amazon RDS for Db2 as a target for mainframe and i Series replication, empowering customers to seamlessly move Db2 data and workloads to AWS.

Global Orphan Drug Growth Opportunities Analysis - Reduced Exclusivity and Increased Competition will Drive Demand for More Efficient R&D and Digital Solutions - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 2, 2024
Health, Pharmaceutical, ODD, IRA, Data wrangling, Informatics, Growth, Patient, Public, Neoplasm, Research, Health care, Cancer, ODS, Medicine, Investment, RDS, US FDA, Nanomedicine, RD, Inflation, OD, SME, Multiomics, Pharmaceutical industry

The "Global Orphan Drug Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Orphan Drug Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.
  • This study provides critical insights into the global orphan drug (OD) industry and highlights growth opportunities, revenue, regulatory changes, and technology trends influencing growth.
  • The growing number of unaddressed RD needs is a major catalyst for R&D.
  • There is a need for novel medicine to treat RDs that currently have limited therapeutic choices.